A61K 2239/17
Hinge-spacer domain
A61K2239/17 (Hinge-spacer domain) appears on 53 US grants and 302 published applications in this corpus.
Search patents in A61K- Granted patents
- 53
- Published applications
- 302
- Assignees
- 183
- Inventors
- 876
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 2 |
| 2015 | 0 | 1 |
| 2016 | 0 | 4 |
| 2017 | 1 | 5 |
| 2018 | 1 | 5 |
| 2019 | 2 | 5 |
| 2020 | 8 | 14 |
| 2021 | 1 | 13 |
| 2022 | 4 | 13 |
| 2023 | 4 | 23 |
| 2024 | 10 | 90 |
| 2025 | 11 | 79 |
| 2026 | 11 | 48 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Methods and compositions for chimeric antigen receptor targeting cancer cells1 Sep 2026US 12,721,892 B2The University of North Carolina at Chapel Hill
- Antigen-binding protein targeting CD70 and use thereof1 Sep 2026US 12,721,893 B2
- Polypeptide specific for mucin 1 and use thereof23 Jun 2026US 12,661,402 B2LG Chem.Ltd.
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Coreceptor chimeric antigen receptor24 Sep 2026US 2026/0284111 A1
- Methods and compositions for treating autoimmune diseases17 Sep 2026US 2026/0272983 A1Cabaletta Bio, Inc.
- Disruption of telocyte activity10 Sep 2026US 2026/0263514 A1
- Nucleic acid molecule comprising intracellular signaling domain and nkp30 transmembrane domain and chimeric antigen receptor comprising the same10 Sep 2026US 2026/0263515 A1Pell Bio-Med Technology Co., Ltd.
Most cited
By later US patents
- CD123-specific chimeric antigen receptor redirected T cells and methods of their use27US 9,657,105 B2City of Hope · 2017
- Method and compositions for cellular immunotherapy21US 10,736,918 B2Fred Hutchinson Cancer Research Center · 2020
- Cell19US 10,172,885 B2UCL Business PLC · 2019
- Method and compositions for cellular immunotherapy19US 10,780,118 B2Fred Hutchinson Cancer Research Center · 2020
- Chimeric antigen and T cell receptors and methods of use18US 10,603,380 B2Kite Pharma, Inc. · 2020